The overexpression of FOXD2-AS1 can overcome drug resistance in sorafenib-resistant HCC cells by increasing TMEM9 expression, whereas the knockdown of FOXD2-AS1 decreases TMEM9 expression and increases sensitivity to sorafenib in HCC cells, suggesting that FOXD2 could serve as a therapeutic target for HCC. The gene discussed is TMEM9; the disease is hepatocellular carcinoma.